Clinical trials: Synucleinopathy
Parkinson's Disease
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor…
- Trial name
- NCT01286935
- Testing
- Safinamide
- Volunteers
- 544 people
- Sponsor
- Newron Pharmaceuticals SPA
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals
Parkinson Disease
Utilization of Target Ranges to Treat Parkinson's Disease With the PKG
The main objective of this study is to evaluate whether people whose PD symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved PD symptoms and outcomes as compared…
- Trial name
- TARGET-PD (NCT03984305)
- Testing
- Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report
- Where
- 17 sites in United States
- Volunteers
- 41 people
- Sponsor
- Global Kinetics Corporation
Parkinson Disease
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate…
- Trial name
- NCT07566429
- Testing
- AB-1005
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Bayer
Parkinson Disease
Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.
- Trial name
- NCT00624741
- Testing
- Pergolide
- Sponsor
- Bausch Health Americas, Inc.
Parkinson's Disease, Essential Tremor
Evaluation of Directional Recording and Stimulation Using spiderSTN
The purpose of this study is to provide proof-of-concept that directional stimulation and directional recording, in an intraoperative setting, is perceivable in a subject.
- Trial name
- NCT02894567
- Testing
- Intraoperative test during a deep brain stimulation surgery
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Aleva Neurotherapeutics SA
Dementia With Lewy Bodies (DLB)
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT01278407
- Testing
- Donepezil 5 mg, Donepezil 10 mg
- Where
- 56 sites in Japan
- Volunteers
- 142 people
- Sponsor
- Eisai Co., Ltd.
Multiple System Atrophy
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
- Trial name
- TOPAS-MSA (NCT06568237)
- Testing
- TEV-56286
- Where
- 61 sites in United States, France and 6 more
- Volunteers
- 349 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Parkinson's Disease
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
- Trial name
- NCT00203177
- Testing
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 254 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease Dementia, Dementia With Lewy Bodies
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
- Trial name
- NCT04831281
- Testing
- ATH-1017
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- LeonaBio
Parkinson Disease, Movement Disorders
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
- Trial name
- NCT05636852
- Testing
- Altropane (123I) Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- GE Healthcare
Parkinson Disease
Single Ascending Doses of HER-096 in Healthy Subjects
This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline).
- Trial name
- NCT05915247
- Testing
- HER-096
- Where
- Finland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Herantis Pharma Plc.
Parkinson's Disease
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
- Trial name
- ADAGIO (NCT00256204)
- Testing
- Rasagiline Mesylate
- Volunteers
- 1,174 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or…
- Trial name
- NCT00650104
- Testing
- Ropinirole XL (formerly CR)
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
- Trial name
- ANDANTE (NCT01049984)
- Testing
- Rasagiline
- Where
- 58 sites in United States
- Volunteers
- 328 people
- Sponsor
- Teva Neuroscience, Inc.
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Parkinson Disease
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
This study is double-blinded placebo controlled followed by an open-label extension placebo-to-active switch to estimate the efficacy of Talineuren.
- Trial name
- LIBRA (NCT06431971)
- Testing
- Talineuren
- Where
- 6 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- InnoMedica Schweiz AG
Parkinson Disease
STEPS Trial - Spheramine Safety and Efficacy Study
The purpose of the study is to explore the safety, tolerability and efficacy of Spheramine (cultured human retinal pigment epithelial cells on microcarriers) in Parkinson's Disease patients with advanced disease who have…
- Trial name
- NCT00206687
- Testing
- Spheramine (BAY86-5280)
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.
Parkinson's Disease
Effectiveness and Safety of Directional Deep Brain Stimulation for Parkinson's Disease
The purpose of this study is to demonstrate the safety and effectiveness of the PINS Deep Brain Stimulation (DBS) system, including the G107R/G107 IPG, L305/L306 directional leads, E204 extensions and related system components.
- Trial name
- NCT05992701
- Testing
- Directional deep brain stimualtion
- Where
- 9 sites in China
- Volunteers
- 26 people
- Sponsor
- Beijing Pins Medical Co., Ltd